Anthem Bioscienc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0CZ201020
  • NSEID: ANTHEM
  • BSEID: 544449
INR
645.90
12.75 (2.01%)
BSENSE

Mar 20

BSE+NSE Vol: 1.87 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.87 lacs (15.60%) Volume

Shareholding (Dec 2025)

FII

1.36%

Held by 48 FIIs

DII

0.27%

Held by 20 DIIs

Promoter

74.69%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

View full answer

When is the next results date for Anthem Biosciences Ltd?

28-Jan-2026

The next results date for Anthem Biosciences Ltd is February 5, 2026.

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026.

View full answer

Should I buy, sell or hold Anthem Biosciences Ltd?

10-Mar-2026

Why is Anthem Biosciences Ltd falling/rising?

17-Mar-2026

As of 16-Mar, Anthem Biosciences Ltd's stock price is rising to 643.60, indicating a potential shift in market sentiment after a decline. However, concerns about declining sales, profitability, and reduced investor participation suggest caution may be warranted despite today's positive movement.

As of 16-Mar, Anthem Biosciences Ltd's stock price is rising, currently at 643.60, with a change of 3.7 (0.58%) upward. This increase follows a trend reversal after three consecutive days of decline, indicating a potential shift in market sentiment. The stock has outperformed its sector by 1.7% today, suggesting that it is gaining relative strength compared to its peers.<BR><BR>Despite this positive movement, the stock has been trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume on March 13 falling by 97.76% against the 5-day average, which could signal a lack of confidence among investors.<BR><BR>On the financial side, while the company shows high management efficiency with a return on equity (ROE) of 19.93% and a low debt-to-equity ratio, recent negative results have raised concerns. The profit before tax (PBT) has decreased by 24.2% compared to the previous four-quarter average, and the net sales for the last quarter were the lowest at Rs 423.15 crore. These factors contribute to a perception of an expensive valuation, with a price-to-book value of 12.7, despite the stock's profits rising by 35% over the past year.<BR><BR>In summary, while the stock is experiencing a rise today, the underlying issues related to declining sales and profitability, along with reduced investor participation, suggest that caution may still be warranted.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Negative results in Dec 25

  • PBT LESS OI(Q) At Rs 122.31 cr has Fallen at -24.2% (vs previous 4Q average)
  • NET SALES(Q) At Rs 423.15 cr has Fallen at -18.3% (vs previous 4Q average)
  • PAT(Q) At Rs 110.87 cr has Fallen at -14.1% (vs previous 4Q average)
2

With ROE of 17.7, it has a Very Expensive valuation with a 12.7 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 36,287 Cr (Mid Cap)

stock-summary
P/E

72.00

stock-summary
Industry P/E

31

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.34

stock-summary
Return on Equity

17.74%

stock-summary
Price to Book

12.56

Revenue and Profits:
Net Sales:
423 Cr
(Quarterly Results - Dec 2025)
Net Profit:
93 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.92%
0%
-4.92%
6 Months
-23.72%
0%
-23.72%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Cessation

13-Mar-2026 | Source : BSE

Anthem Biosciences Limited hereby informs the exchange of the resignation of Mr. K Ramakrishnan from the position of General Counsel and consequently from the role of Senior Management Personnel of the Company with effect from March 31 2026.

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)

23-Feb-2026 | Source : BSE

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2025 we hereby inform that the Company has executed on February 23 2026 First amendment to the Loan agreement dated April 15 2024 entered with Neoanthem Lifesciences Private Limited (Wholly Owned Subsidiary).

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

09-Feb-2026 | Source : BSE

Earnings Call Transcript for Q3 FY26

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
29.80%
EBIT Growth (5y)
44.32%
EBIT to Interest (avg)
56.77
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.62
Tax Ratio
28.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.96%
ROCE (avg)
32.59%
ROE (avg)
19.93%

Valuation key factors

Factor
Value
P/E Ratio
72
Industry P/E
31
Price to Book Value
12.71
EV to EBIT
57.77
EV to EBITDA
51.24
EV to Capital Employed
18.83
EV to Sales
19.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
32.59%
ROE (Latest)
17.74%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
Bollinger Bands
Mildly Bearish
KST
Dow Theory
No Trend
No Trend
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 22 Schemes (6.89%)

FIIs

Held by 48 FIIs (1.36%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Viridity Tone Llp (3.8%)

Individual Investors Holdings

9.6%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "416.58",
          "val2": "552.23",
          "chgp": "-24.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "163.05",
          "val2": "225.66",
          "chgp": "-27.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.13",
          "val2": "2.23",
          "chgp": "-49.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "112.12",
          "val2": "198.43",
          "chgp": "-43.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.14%",
          "val2": "40.86%",
          "chgp": "-1.72%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,506.82",
          "val2": "1,361.66",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "584.13",
          "val2": "490.89",
          "chgp": "18.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "6.99",
          "chgp": "-28.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "458.89",
          "val2": "383.62",
          "chgp": "19.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.77%",
          "val2": "36.05%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,840.65",
          "val2": "1,417.54",
          "chgp": "29.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.01",
          "val2": "504.89",
          "chgp": "36.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.09",
          "val2": "9.14",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "506.19",
          "val2": "374.78",
          "chgp": "35.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.43%",
          "val2": "35.62%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
416.58
552.23
-24.56%
Operating Profit (PBDIT) excl Other Income
163.05
225.66
-27.75%
Interest
1.13
2.23
-49.33%
Exceptional Items
-24.98
0.00
Standalone Net Profit
112.12
198.43
-43.50%
Operating Profit Margin (Excl OI)
39.14%
40.86%
-1.72%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
1,090.24
863.40
26.27%
Operating Profit (PBDIT) excl Other Income
421.08
324.04
29.95%
Interest
3.84
5.20
-26.15%
Exceptional Items
0.00
0.00
Standalone Net Profit
346.77
255.63
35.65%
Operating Profit Margin (Excl OI)
38.62%
37.53%
1.09%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,506.82
1,361.66
10.66%
Operating Profit (PBDIT) excl Other Income
584.13
490.89
18.99%
Interest
4.97
6.99
-28.90%
Exceptional Items
-24.98
0.00
Standalone Net Profit
458.89
383.62
19.62%
Operating Profit Margin (Excl OI)
38.77%
36.05%
2.72%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
1,840.65
1,417.54
29.85%
Operating Profit (PBDIT) excl Other Income
689.01
504.89
36.47%
Interest
9.09
9.14
-0.55%
Exceptional Items
0.00
0.00
Standalone Net Profit
506.19
374.78
35.06%
Operating Profit Margin (Excl OI)
37.43%
35.62%
1.81%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About Anthem Biosciences Ltd stock-summary
stock-summary
Anthem Biosciences Ltd
Mid Cap
Pharmaceuticals & Biotechnology
Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.
Company Coordinates stock-summary
Icon
No Company Details Available